Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy by 源��쁽二� et al.
│ http://www.e-crt.org │ 669Copyright ⓒ 2017 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2017;49(3):669-677
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2016.354  
Open Access
Dose-Response Relationship between Radiation Dose and 
Loco-regional Control in Patients with Stage II-III Esophageal Cancer
Treated with Definitive Chemoradiotherapy
Original Article
Purpose
The correlation between radiation dose and loco-regional control (LRC) was evaluated in
patients with stage II-III esophageal cancer treated with definitive concurrent chemoradio-
therapy (CRT).
Materials and Methods
Medical records of 236 stage II-III esophageal cancer patients treated with definitive CRT at
Yonsei Cancer Center between 1994 and 2013 were retrospectively reviewed. Among these,
120 received a radiation dose of < 60 Gy (standard-dose group), while 116 received ! 60
Gy (high-dose group). The median doses of radiation in the standard- and high-dose groups
were 50.4 and 63 Gy, respectively. Concurrent 5-fluorouracil/cisplatin chemotherapy was
administered to most patients.
Results
There were no differences in patient characteristics between the two groups except for high
Karnofsky performance status and lower-thoracic lesions being more prevalent in the stan-
dard-dose group. The median progression-free survival (PFS) and overall survival (OS) times
were 13.2 months and 26.2 months, respectively. Patients in the high-dose group had sig-
nificantly better 2-year LRC (69.1% vs. 50.3%, p=0.002), median PFS (16.7 months vs.
11.7 months, p=0.029), and median OS (35.1 months vs. 22.3 months, p=0.043). Addi-
tionally, LRC exhibited a dose-response relationship and the complete response rate was
significantly higher in the high-dose group (p=0.006). There were no significant differences
in treatment-related toxicities between the groups. 
Conclusion
A higher radiation dose (> 60 Gy) is associated with increased LRC, PFS, and OS in patients
with stage II-III esophageal cancer treated with definitive CRT.
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Introduction
Esophageal cancer ranks ninth in cancer incidences and
sixth in cancer-related deaths globally [1]. More than half of
esophageal cancer patients are diagnosed with locally 
advanced disease and approximately 20% have resectable
disease at presentation [2]. Even in patients with resectable
disease, prognosis is poor after surgical resection alone, with
a 5-year survival rate of < 30% [3,4].
Definitive chemoradiotherapy (CRT) has been recom-
mended as the optimal treatment for patients who are med-
ically inoperable or have an unresectable tumor based on the
results of the Radiation Therapy Oncology Group (RTOG)
85-01 trial [5-7], which showed a statistically significant sur-
vival benefit with CRT compared to radiotherapy (RT) alone
(5-year overall survival [OS], 26% vs. 0%, respectively). The
RTOG 94-05 trial further compared OS and loco-regional
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control (LRC) with respect to combined-modality therapy
using standard-dose 50.4 Gy versus 64.8 Gy of RT for 
patients with locally advanced esophageal cancer and found
no significant advantage to administering high-dose radia-
tion with respect to LRC and OS [8,9]. 
Although the recommended dose of RT has remained 50.4
Gy in the definitive CRT setting based on the results of the
RTOG 94-05 trial [10], the optimal radiation dose is still con-
troversial. This study was designed to investigate the corre-
lation between radiation dose and LRC in patients with stage
II-III esophageal cancer treated with definitive CRT. 
Materials and Methods
1. Patient characteristics 
We identified all patients treated with CRT for clinical
stage II-III esophageal cancer at Yonsei Cancer Center 
between February 1994 and May 2013. Overall, 418 patients
were retrospectively reviewed, among which 182 were 
excluded because of the following reasons: (1) low-dose RT
administered as a palliative measure (n=22), (2) incomplete
treatment (n=16), (3) esophagectomy after CRT (n=80), (4)
other primary cancer history (n=11), (5) intraluminal
brachytherapy (n=46), and (6) follow-up loss after CRT (n=7).
Ultimately, 236 patients were included in this analysis, and
their electronic medical records were retrospectively 
reviewed.
Pretreatment evaluation included previous medical his-
tory, physical examination, symptoms, and performance sta-
tus. Laboratory studies included a complete blood cell count
and routine chemistry. For staging workup, barium swallow,
esophagogastroduodenoscopy (EGD), transesophageal 
endoscopic ultrasonography, and computed tomography
(CT) of the chest and abdomino-pelvis were performed. For
evaluation of distant metastases, patients underwent whole-
body bone scanning and 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET).
2. Treatment
RT was performed with three-dimensional conformal RT
(3D-CRT) or intensity-modulated RT (IMRT) with helical 
tomotherapy (Tomotherapy Inc., Madison, WI) starting on
day 1 of chemotherapy. A conventional fractionation sched-
ule (daily 1.8-2.0 Gy per fraction, 5 days per week) and cone-
down technique were used in all patients. The gross tumor
volume (GTV) was delineated using positron emission 
tomography and CT fusion on the MIM software (Cleveland,
OH) or Pinnacle Radiotherapy Planning System (Phillips
Medical System, Andover, MA). The initial clinical target
volume (CTV) included the GTV plus a margin of at least 5
cm longitudinally and 2 cm radially. The initial CTV received
30.6-50.4 Gy (median dose, 36 Gy) with anterior-posterior
parallel opposite fields to reduce lung dose. At the time of
cone-down, final CTV encompassed the GTV with a 2 cm
margin longitudinally and radially. The total radiation dose
ranged from 45.0 to 66.6 Gy, with a median dose of 63 Gy.
Chemotherapy was administered to all patients using a 
5-fluorouracil (5-FU)–based regimen, except for five patients
(2.1%) who underwent cisplatin alone because of their med-
ical condition. Overall, 217 patients (91.9% of all patients)
were treated with a 5-FU/cisplatin (FP) regimen, while 14
(5.9%) underwent 5-FU monotherapy. During RT, two cycles
of FP chemotherapy were administered concurrently. 
Patients had a 4-week break after completing RT, after which
they received additional maintenance chemotherapy if a
medical oncologist determined that their performance status
and medical condition would allow this. 5-FU was adminis-
tered at 500-1,250 mg/m2 daily as a continuous infusion
using a portable electronic pump on days 1-4, while cisplatin
was administered at 40-100 mg/m2 on day 1 and during RT
sessions. 
3. Follow-up 
All patients were examined weekly during RT to monitor
treatment toxicities and their general condition. After com-
pletion of CRT, patients were followed at 3-month intervals
for the first 3 years, 6-month intervals for the next 2 years,
and annually thereafter. Follow-up sessions included phys-
ical examination, barium swallow, chest CT, FDG-PET, EGD,
and toxicity evaluation. Treatment-related toxicities were
recorded according to the Common Toxicity Criteria for 
Adverse Events ver. 4.0. Tumor response was assessed
pathologically based on endoscopic biopsy, as well as clini-
cally based on follow-up imaging studies within three
months of completion of CRT according to the Response
Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1. 
Recurrences were confirmed histologically or using conclu-
sive imaging studies if pathological confirmation was not
achieved. If loco-regional recurrences were confirmed, they
were classified into central, marginal, or outfield based on
the location of the recurrent tumor. Marginal recurrences
were defined as recurred tumors located inside the initial RT
field, but outside of the cone-down RT field. Disease recur-
rences outside of the esophagus and regional lymph nodes
were considered distant metastases.
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4. Statistical analysis 
Patients were grouped by total radiation dose, with the
high-dose group receiving ! 60 Gy and the standard dose
group < 60 Gy. Study endpoints were LRC and survival. Sur-
vival duration was calculated from the date of diagnosis to
the corresponding event (loco-regional recurrence, distant
metastasis [DM], or death). Continuous variables between
the two groups were compared using independent t tests
based on baseline characteristics. The Pearson’s chi-square
test or Fisher exact test were used as appropriate to compare
categorical variables. The Kaplan-Meier method with log-
rank test was used to analyze survival outcomes between
groups. Multivariate analysis using the stepwise Cox pro-
portional hazards regression model was performed to iden-
tify prognostic factors for LRC and OS (inclusion criteria, 
p < 0.10). All statistical tests were two-sided with significance
defined as p < 0.05. Data were analyzed using the IBM SPSS
software ver. 20.0 (IBM Corp., Armonk, NY).
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Table 1. Patient characteristics
Characteristic Standard dose High dose p-value(n=120) (n=116)
Age, mean (range, yr) 66.0 (41-81) 67.0 (30-86) 0.924
Sex
Male 114 (95.0) 112 (96.6) 0.749
Female 6 (5.0) 4 (3.4)
Karnofsky performance status
90-100 97 (80.8) 77 (67.2) 0.017
60-80 23 (19.2) 38 (32.8)
Pathology
Squamous cell carcinoma 117 (97.5) 113 (97.4) 0.879
Adenocarcinoma 3 (2.5) 3 (2.6)
Histologic grade
Well differentiated 15 (12.5) 11 (9.5) 0.887
Moderately differentiated 60 (50.0) 58 (50.0)
Poorly differentiated 34 (28.3) 36 (31.0)
Unknown 11 (9.2) 11 (9.5)
Tumor length (cm)
& 5 66 (55.0) 58 (50.0) 0.442
> 5 54 (45.0) 58 (50.0)
Tumor location
Cervical 5 (4.2) 11 (9.5) 0.038
Upper thoracic 27 (22.5) 31 (26.7)
Mid thoracic 55 (45.8) 58 (50.0)
Lower thoracic 33 (27.5) 16 (13.8)
Clinical T stage
cT1 10 (8.4) 8 (6.9) 0.828
cT2 27 (22.5) 23 (19.8)
cT3 64 (53.3) 62 (53.5)
cT4 19 (15.8) 23 (19.8)
Clinical N stage
cN0 19 (15.8) 12 (10.3) 0.555
cN1 86 (71.7) 90 (77.6)
cN2 14 (11.7) 12 (10.3)
cN3 1 (0.8) 2 (1.8)
Stage
II 46 (38.3) 32 (27.6) 0.079
III 74 (61.7) 84 (72.4)
Values are presented as number (%). 
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Results
Of the 236 patients analyzed in our study, 120 received 
< 60 Gy of RT (standard-dose group) and 116 patients 
received ! 60 Gy (high-dose group). Patient characteristics
are shown in Table 1. No statistically significant differences
were observed between groups with respect to age, sex, his-
tologic subtype, tumor length, clinical T stage, N stage, or
clinical stage distribution. Most patients were male (96%)
and had squamous cell carcinoma (97.5%). More patients
with stage III disease were included in the high-dose group,
although the difference was not significant (72.4% vs. 61.7%,
p=0.079). Karnofsky performance status and tumor location
were the only factors that showed statistically significant dif-
ferences between the two groups, and there were more 
patients with better performance statuses and lower thoracic
esophageal tumors in the standard-dose group. Initial FDG-
PET was performed in 71.2% of all patients, with no signifi-
cant difference between groups (76.7% in the standard-dose
group vs. 65.5% in the high-dose group).
1. Details regarding treatment and follow-up
Patient treatment details are summarized in Table 2. Most
patients received FP-based chemotherapy, and the propor-
tion of patients treated with FP was similar between groups
(p=0.742). The median doses of 5-FU and cisplatin were also
similar in both groups. Maintenance chemotherapy follow-
ing CRT was administered to 147 patients (62.3%), including
66 in the standard-dose group and 81 in the high-dose group
(55% vs. 69.8% respectively, p=0.019). With the exception of
four patients who underwent IMRT with tomotherapy, RT
was performed with 3D-CRT. The median radiation dose
was 50.4 Gy (range, 45 to 59.4 Gy) in the standard-dose group
and 63 Gy (range, 60 to 66.6 Gy) in the high-dose group. The
median follow-up period was 19.4 months (range, 2.2 to 164.7
months) for all patients and 50.8 months (range, 4.9 to 164.7
months) for those who survived.
2. Survival outcomes and tumor response
The median OS and progression-free survival (PFS) times
for all patients were 26.2 months and 13.2 months, respec-
tively. Comparisons of LRC, distant metastasis-free survival
(DMFS), PFS, and OS between the two dose groups are
shown in Fig. 1. All endpoints except DMFS were found to
have statistically significant differences favoring the high-
dose group. The 2-year and 5-year LRC rates of all patients
were 60.0% and 48.4%, respectively. The 5-year LRC rates
were significantly different between groups (59.7% in the
high-dose group and 37.3% in the standard-dose group,
p=0.002) (Fig. 1A). Although DMFS rates were not signifi-
cantly different according to the RT dose, PFS rates were sig-
Cancer Res Treat. 2017;49(3):669-677
Table 2. Treatment characteristics
Characteristic Standard dose High dose p-value(n=120) (n=116)
RT modality
3D-CRT 119 (99.2) 113 (97.4) 0.363
IMRT 1 (0.8) 3 (2.6)
RT dose, median (range, Gy)
Total 50.4 (45.0-59.4) 63.0 (60.0-66.6) < 0.001
Fractional 1.8 (1.8-2.5) 1.8 (1.8-2.0)
Chemotherapy regimen
5-Fluorouracil+cisplatin 111 (92.5) 106 (91.4) 0.742a)
5-Fluorouracil monotherapy 6 (5.0) 8 (6.9)
Others 3 (2.5) 2 (1.7)
Median dose of chemotherapy
5-Fluorouracil (mg/m2) 1,000 (500-1,250) 1,000 (500-1,250) 0.942
Cisplatin (mg/m2) 80 (40-100) 80 (50-100) 0.470
Maintenance chemotherapy
Yes 66 (55.0) 81 (69.8) 0.019
No 54 (45.0) 35 (30.2)
Values are presented as number (%). 3D-CRT, 3 dimensional-conformal radiotherapy; IMRT, intensity-modulated radiother-
apy; RT, radiotherapy. a)Fisher exact test. 
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nificantly different between the two dosing groups (median
PFS, 11.7 months vs. 16.7 months in the standard-dose and
high-dose groups, respectively; p=0.029) (Fig. 1B and C). Fur-
thermore, OS rates were significantly different between 
patients treated with < 60 Gy and ! 60 Gy (median, 22.3
months vs. 35.1 months, respectively; p=0.043) (Fig. 1D). 
Radiation doses were grouped into intervals of 5 Gy and
plotted against LRC durations to investigate whether a dose-
response relationship exists between RT dose and LRC 
(Fig. 2). A positive correlation was observed between RT
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Fig. 1. Kaplan-Meier curves of locoregional control (LRC) (A), distant metastasis-free survival (DMFS) (B), progression-free
survival (PFS) (C), and overall survival (OS) (D).
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dose and LRC rate in the setting of definitive CRT.
The total treatment response rate was 94% for all patients.
Complete response (CR) was achieved in 125 patients (53%),
including 53 in the standard-dose group and 72 in the high-
dose group. CR rates were significantly higher in the high-
dose group than in the standard-dose group (62.1% vs.
44.2%, respectively; p=0.006). The partial response rates were
47.5% in the standard-dose group and 34.5% in the high-dose
group. The rates of stable disease (SD) and progressive dis-
ease (PD) were 5.0% and 3.3% in the standard-dose group,
while they were 2.6% and 0.9% in the high-dose group, 
respectively, with no significant differences (SD, p=0.500; PD,
p=0.186). The failure patterns are summarized in Table 3. A
total of 141 patients (59.7%) experienced treatment failures,
including loco-regional failure (LRF) alone in 77 patients
(32.6%), DM alone in 50 (21.2%), and both LRF and DM in 14
(5.9%). The number of patients with LRF alone differed sig-
nificantly between two groups (39.2% vs. 25.9% in the stan-
dard-dose vs. high-dose groups, respectively; p=0.029). The
rate of central failures was two-fold higher in the standard-
dose group (26.7% vs. 12.1%, p=0.005), and DM occurred
more frequently in the high-dose group (25.9% vs. 16.7%,
p=0.023). 
3. Prognostic factors and treatment-related toxicities
The results of univariate and multivariate analyses are
shown in Table 4. Univariate analysis revealed that RT dose
and the use of maintenance chemotherapy were significant
prognostic factors associated with LRC. Multivariate analysis
showed that RT dose ! 60 Gy and the use of maintenance
chemotherapy remained independent predictors of impro-
ved LRC. For OS, Karnofsky performance status, clinical T
stage, American Joint Committee on Cancer (AJCC) stage,
RT dose, pretreatment stricture, and the use of maintenance
chemotherapy were found to be significant risk factors upon
univariate analysis. Finally, multivariate analysis identified
clinical stage, RT dose ! 60 Gy, and use of maintenance
chemotherapy as independent prognostic factors correlated
with OS. 
Treatment-related toxicities of grade ! 2 occurred in 38 
patients, with 19 in each of the standard-dose and high-dose
groups. No significant differences was found between
groups (p=0.929). Toxicities of grades ! 3 occurred in 21 
patients, with six patients in each group having grade 3
esophageal stenosis, one in the high-dose group having
grade 3 mediastinitis and two in the standard-dose group
having grade 3 radiation-induced pneumonitis. Moreover,
one patient in each group had a grade 3 fistula, while one in
the high-dose group had a grade 4 fistula. Three patients had
treatment-related grade 5 toxicities, with two in the standard-
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Fig. 2. Dose response relationship between radiotherapy
(RT) dose and loco-regional control (LRC) durations.
Table 3. Pattern of failures
Primary tumor response Standard-dose group High-dose group p-value(< 60 Gy) (! 60 Gy)
LRF only 47 (39.2) 30 (25.9) 0.029
Central failure 32 (26.7) 14 (12.1) 0.005
Marginal failure 4 (3.3) 6 (5.2) 0.534a)
Out-field failure 11 (9.2) 10 (8.6) 0.883
DM only 20 (16.7) 30 (25.9) 0.023
Both LRF and DM 8 (6.7) 6 (5.2) 0.627
Total 75/120 (62.5) 66/116 (57.0)
Values are presented as number (%). LRF, loco-regional failure; DM, distant metastasis. a)Fisher exact test.
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dose group dying from an esophageal fistula and esophageal
perforation, respectively, and one in the high-dose dying
from massive esophageal hemorrhage. These patients were
all receiving maintenance chemotherapy after the end of CRT
when they died, having EGD-confirmed residual tumors.
Discussion
In this study, we investigated the correlation between 
radiation dose and LRC in patients with stage II-III
esophageal cancer treated with definitive CRT. The results
of the current study suggest that patients who received a
total dose ! 60 Gy of RT had significantly better LRC, PFS,
and OS than patients receiving < 60 Gy when treated with
concurrent chemotherapy. Furthermore, our data suggest the
existence of a positive correlation between radiation dose
and LRC rate.
Based on the results of the RTOG 85-01 trial [5], definitive
CRT was established as the standard treatment option for 
localized esophageal cancer selected for nonsurgical treat-
ment. In this trial, the 5-year OS rate was 26% for patients in
the combined-modality group and 0% for those in the RT-
alone group (p < 0.001). Persistent tumors were also less com-
mon in the combined modality group (26% vs. 37%), as were
distant metastases as the first site of treatment failure (16%
vs. 30%). The radiation dose of 50 Gy used for the combined-
modality arm in the RTOG 85-01 trial became a preferred
dose of RT in definitive CRT settings. 
However, this dose requires further investigation because
50 Gy of radiation with conventional fractionations is gener-
ally considered inadequate to control gross tumors [11,12].
In the RTOG 94-05 phase III trial, the optimal radiation dose
was further investigated [8,9]. A total of 236 patients with 
locally advanced esophageal cancer were randomly selected
to receive a combined therapy consisting of FP chemother-
apy concurrently with high-dose (64.8 Gy) versus standard-
dose (50.4 Gy) RT. There were no significant differences in
median survival (13.0 months vs. 18.1 months), 2-year sur-
vival (31% vs. 40%), or LRF and loco-regional persistence of
disease (56% vs. 52%) between the high-dose and standard-
dose groups, respectively. Although 11 treatment-related
deaths occurred in the high-dose group, while there were
only two in the standard-dose arm, seven of the 11 deaths
occurred before the radiation dose reached 50.4 Gy. More-
over, the radiation technique used in that study was two-
dimensional, and the margins applied to the target volume
were larger than those used in current practice, which may
have increased the probability of toxicities. Furthermore, a
significantly lower dose of 5-FU was administered to patients
Hyun Ju Kim, Dose-Response Relationship between RT Dose and LRC
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in the high-dose arm, which could have negatively affected
the outcomes of the high-dose arm. Because of such draw-
backs, the benefit of high-dose RT with modern techniques
remains controversial.
Several studies have attempted to verify the benefit of 
radiation dose escalation in definitive CRT for locally 
advanced esophageal cancer [13-15]. Zhang et al. [14] inves-
tigated 69 patients with stage II-III unresectable esophageal
cancer treated with CRT, including 43 who received & 51 Gy
and 26 who received > 51 Gy. They found that patients in the
higher dose group had better 3-year local control (36% vs.
19%) and disease-free survival (25% vs. 10%) than those in
the low-dose group, but that OS was not significantly differ-
ent (13% vs. 3%, p=0.054). The complete clinical response rate
was also significantly greater in the high-dose group (46%
vs. 23%, p=0.048). However, their study was limited owing
to its small number of patients, retrospective setting, and
varying fractionation schedules in the standard-dose arm 
(30 Gy in 10 fractions). The results of a phase II study also 
revealed that selective radiation dose escalation in definitive
CRT settings yields promising results without surgery or 
adjuvant chemotherapy [13]. The preliminary results from
our previous report [16] suggested a benefit for high-dose RT
in stage II-III esophageal cancer patients. The effects of RT 
! 60 Gy with concurrent chemotherapy were evaluated in
126 patients. The high-dose group showed significantly 
improved LRC (2-year LRC rate, 69% vs. 32%; p < 0.01) and
PFS (2-year PFS, 47% vs. 20%; p=0.01) relative to the stan-
dard-dose group. However, there was no significant differ-
ence in OS between groups (median, 28 months vs. 18
months respectively; p=0.26).
In this study, we included a relatively large number of 
patients, all of whom received RT with conventional fraction-
ations (1.8-2.0 Gy per fraction) and modern techniques (3D-
CRT or IMRT). For all patients, the median OS and PFS rates
were 26.2 and 13.2 months, respectively, which were more
favorable than the results of other studies [17]. In the RTOG
94-05 trial [8], the median survival was 18.1 months in the
standard-dose arm and 13.0 months in the high-dose arm. In
the FFCD 9102 trial [18,19], which compared CRT alone to
CRT followed by surgery in patients with locally advanced
tumors, the median OS was 19.3 months in the CRT arm. In
a study conducted by Hurmuzlu et al. [20], 46 patients were
treated with high-dose RT (66 Gy in 33 fractions) concur-
rently with FP chemotherapy. The median OS and disease-
specific survival were only 10.8 months and 11 months,
respectively.
Radiation dose to the heart was recently reported to have
adverse effects on survival, with mean heart dose noted in
patients with breast cancer and with V5 and V30 noted in
lung cancer patients in the RTOG 0617 trial [21,22]. Although
a study conducted to determine the independent impact of
heart dose on early OS revealed that heart dose was not 
associated with early survival outcomes when lung dose was
taken into account [23], heart dose should not be overlooked
during RT planning. Heart dose is also a concern during
treatment planning for esophageal cancer because of the
close proximity between the two organs. Therefore, we per-
formed survival analysis according to the tumor location by
dividing patients into those with lower thoracic tumors and
those with tumors in other locations. High-dose radiation 
! 60 Gy showed no significant OS benefit in patients with
lower thoracic lesions (hazard ratio [HR], 0.681; 95% confi-
dence interval [CI], 0.288 to 1.612; p=0.382). Conversely, OS
was significantly better in patients with tumors in other 
locations (HR, 0.678; 95% CI, 0.467 to 0.985; p=0.041). These
results indicate a possible detrimental effect of cardiac dose
on early survival in esophageal cancer patients. Accordingly,
follow-up studies are warranted to assess the effects of car-
diac dose on heart disease or mortality.
It should be noted that this study had several limitations.
Specifically, this study has limitations stemming from its ret-
rospective nature. Moreover, the chemotherapy regimens
used for the patients and the use of maintenance chemother-
apy were not uniform, which may have influenced tumor 
response. Furthermore, patient characteristics were not
matched between the two groups, and patients with good
performance statuses and lower thoracic lesions were signif-
icantly more prevalent in the standard-dose group than in
the high-dose group. Better clinical outcomes in the high-
dose group despite a lower performance status suggest that
the benefit of high-dose RT outweighs this disadvantage. 
Finally, it is possible that treatment-related toxicities were
underestimated due to the study’s retrospective setting. 
Conclusion
Higher radiation dose (! 60 Gy) was found to be associated
with increased LRC, PFS, and OS in patients with stage II-III
esophageal cancer treated with definitive CRT. These results
suggest that radiation dose escalation may improve survival
outcomes for such patients. A prospective trial evaluating
the optimal dose of radiation is warranted in the future.
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